United States Influenza Vaccine Market

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Research Methodology 
DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.
Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.
Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.
All the information gathered was then analysed and synthesized by in–house team of analysts.

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Research Methodology 
DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.
Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.
Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.
All the information gathered was then analysed and synthesized by in–house team of analysts.

Global Influenza Vaccines Market and Forecast to 2021 – Size, Share, Growth and Trends Analysis

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

 

DPI Research publish a new report on “Global Influenza Vaccines Market and Forecast to 2021 – Size, Share, Growth and Trends Analysis”

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

 

DPI Research published a new report on “Seasonal Influenza Vaccine Market”

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

 

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

 

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

Neurostimulation Devices Market

The Global market for Neurostimulation Devices is expected to cross US$5 Billion by the year end of 2021.

Drivers & Restraints

Market growth can be attributed to factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by the players. In addition, rapid advances in the field of neurostimulation and development of minimally invasive techniques have greatly expanded the market. High cost of treatment and negative social perception is restraining the growth of neurostimulation devices Market.

Segment Insights

Spinal cord stimulation segment dominated the neurostimulation devices market with more than XX% share in 2015. But its market share will dwindle in the forecasting period due to the highest growth rate of deep brain stimulation segment. It is expected that deep brain stimulation segment will grab nearly 20% market share by the year end of 2021.

Regional Insights

North America is seen as the dominant player in the neurostimulation devices market followed by Europe, Asia–Pacific, and rest of the world (RoW) in 2015. In the coming years, the neurostimulation devices market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of devices involved in neurostimulation.

Application Insights

Chronic Pain is identified as the largest application segment of the neurostimulation devices market. Urinary and Fecal Incontinence(UFI) is the second leading segment for neurostimulation devices market. Refractory epilepsy stands at the third spot with more than XX% share in 2015. Parkinson’s disease holds the fourth highest share being followed by Gastroparesis. Essential Tremor and Dystonia are the other leading application segment for neurostimulation devices market.

Company Insights

 Further, prudent analysis has been done on the competitor’s part, where three major players grab XX% of the global market by revenue. Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro are the key influencers with their products in the neurostimulation devices market. Merger & acquisitions, partnerships, collaborations and extending distribution networks are few important factors for their dominance.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, application, geographies, companies and market dynamics. The report concludes with the profiles of major players in the global neurostimulation market such as Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro. The major market players are evaluated on various parameters such as company overview, product portfolio, and sales analysis of neurostimulation devices segment from 2010 to 2021. The report also entails major drivers and barriers of neurostimulation devices market.

Neurostimulation Devices Market: Segmentation

Neurostimulation Devices Market is classified on the basis of device segment, application, company and geography.

Based on Segment, Neurostimulation Devices Market can be segmented as follows:

  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Other Devices Segment

Based on Application, Neurostimulation Devices Market can be segmented as follows:

  • Chronic Pain
  • Parkinson’s Disease
  • Urinary Fecal Incontinence
  • Refractory Epilepsy
  • Essential Tremor
  • Dystonia
  • Gastroparesis
  • Treatment Resistant Depression(TRD)
  • Obsessive Compulsive Disorder(OCD)
  • Other Applications

Based on Geography, Neurostimulation Devices Market can be segmented as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Rest of the World (ROW)

Based on Company, Neurostimulation Devices Market can be segmented as follows:

  • Medtronic
  • Boston Scientific
  • St Jude Medical
  • Liva Nova(Cyberonics)
  • Nevro

Neurostimulation Devices Market Insights, Opportunity, Analysis, Market Shares & Forecast 2016 – 2021

The Global market for Neurostimulation Devices is expected to cross US$5 Billion by the year end of 2021.

 Drivers & Restraints

Market growth can be attributed to factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by the players. In addition, rapid advances in the field of neurostimulation and development of minimally invasive techniques have greatly expanded the market. High cost of treatment and negative social perception is restraining the growth of neurostimulation devices Market.

Segment Insights

Spinal cord stimulation segment dominated the neurostimulation devices market with more than XX% share in 2015. But its market share will dwindle in the forecasting period due to the highest growth rate of deep brain stimulation segment. It is expected that deep brain stimulation segment will grab nearly 20% market share by the year end of 2021.

Regional Insights

North America is seen as the dominant player in the neurostimulation devices market followed by Europe, Asia–Pacific, and rest of the world (RoW) in 2015. In the coming years, the neurostimulation devices market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of devices involved in neurostimulation.

Application Insights

Chronic Pain is identified as the largest application segment of the neurostimulation devices market. Urinary and Fecal Incontinence(UFI) is the second leading segment for neurostimulation devices market. Refractory epilepsy stands at the third spot with more than XX% share in 2015. Parkinson’s disease holds the fourth highest share being followed by Gastroparesis. Essential Tremor and Dystonia are the other leading application segment for neurostimulation devices market.

Company Insights

 Further, prudent analysis has been done on the competitor’s part, where three major players grab XX% of the global market by revenue. Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro are the key influencers with their products in the neurostimulation devices market. Merger & acquisitions, partnerships, collaborations and extending distribution networks are few important factors for their dominance.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, application, geographies, companies and market dynamics. The report concludes with the profiles of major players in the global neurostimulation market such as Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro. The major market players are evaluated on various parameters such as company overview, product portfolio, and sales analysis of neurostimulation devices segment from 2010 to 2021. The report also entails major drivers and barriers of neurostimulation devices market.

Neurostimulation Devices Market: Segmentation

Neurostimulation Devices Market is classified on the basis of device segment, application, company and geography.

 Based on Segment, Neurostimulation Devices Market can be segmented as follows:

  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Other Devices Segment

Based on Application, Neurostimulation Devices Market can be segmented as follows:

  • Chronic Pain
  • Parkinson’s Disease
  • Urinary Fecal Incontinence
  • Refractory Epilepsy
  • Essential Tremor
  • Dystonia
  • Gastroparesis
  • Treatment Resistant Depression(TRD)
  • Obsessive Compulsive Disorder(OCD)
  • Other Applications

Based on Geography, Neurostimulation Devices Market can be segmented as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Rest of the World (ROW) 

Based on Company, Neurostimulation Devices Market can be segmented as follows:

  • Medtronic
  • Boston Scientific
  • St Jude Medical
  • Liva Nova(Cyberonics)
  • Nevro